Grant: Doctoral: Vanier Canada Graduate Scholarships
University of Toronto
$150,000.00
Molecularly targeted nanotechnology for enhanced radiation treatment of locally advanced breast cancer.
FY 2008-09
Summary
My research will focus on locally advanced breast cancer (LABC), which has an unusually high and unacceptable mortality with only 1 in 2 patients surviving at 5 years. Locally advanced breast cancers (LABCs) are characterized by their large size, growth into the skin or chest muscle and under the arm. They carry a poor prognosis and it is difficult to prevent cancer recurrence in the breast which typically occurs in 14% to 39% of the cases. To prevent this, we propose to dramatically increase the effect of radiation therapy using gold nanoparticles bound to a drug that specifically targets BC cells. The drug is trastuzumab (Herceptin), which is a drug currently used to treat patients that have aggressive BCs. It has long been known that X-radiation doses delivered to tumors can be greatly enhanced by their interaction with certain materials known as radiosensitizers (RSZ). Preferential delivery of these RSZ to tumors would then provide effective treatment while lowering the side effects associated with high dose radiation treatment. Gold nanoparticles due to their unique properties when exposed to X-rays are excellent candidates to be evaluated as RSZ. Further, gold nanoparticles are well tolerated in the body and are currently under investigation in human trials. We propose to connect trastuzumab to gold nanoparticles, which will deliver gold nanoparticles specifically to BC cells. Once the nanoparticles are loaded in the tumor cells, focused X-rays will be delivered and the gold nanoparticles will produce a spray of electrons inside the tumors. Our laboratory has previously demonstrated that these electrons, called Auger electrons, are highly damaging to the DNA of the BC cells thereby killing them, and two of our products based on this principle are currently in Phase I/II clinical trials. Initial calculations suggest that this novel approach using gold nanoparticles could enhance the cell killing effects by as much as 250 times compared to X-rays alone.
Department
Program
Doctoral: Vanier Canada Graduate Scholarships
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
177898
Name
Chattopadhyay Niladri
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Doctoral Research Awards - A
Projecttitle
Molecularly targeted nanotechnology for enhanced radiation treatment of locally advanced breast cancer.
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$150,000
Cihrequipment2
$0
Programname2
Doctoral: Vanier Canada Graduate Scholarships
Keyworddelim
Herceptin; Locally Advanced Breast Cancer; Nanotechnology; Targeted Therapy; X-Radiation
Abstract
My research will focus on locally advanced breast cancer (LABC), which has an unusually high and unacceptable mortality with only 1 in 2 patients surviving at 5 years. Locally advanced breast cancers (LABCs) are characterized by their large size, growth into the skin or chest muscle and under the arm. They carry a poor prognosis and it is difficult to prevent cancer recurrence in the breast which typically occurs in 14% to 39% of the cases. To prevent this, we propose to dramatically increase the effect of radiation therapy using gold nanoparticles bound to a drug that specifically targets BC cells. The drug is trastuzumab (Herceptin), which is a drug currently used to treat patients that have aggressive BCs. It has long been known that X-radiation doses delivered to tumors can be greatly enhanced by their interaction with certain materials known as radiosensitizers (RSZ). Preferential delivery of these RSZ to tumors would then provide effective treatment while lowering the side effects associated with high dose radiation treatment. Gold nanoparticles due to their unique properties when exposed to X-rays are excellent candidates to be evaluated as RSZ. Further, gold nanoparticles are well tolerated in the body and are currently under investigation in human trials. We propose to connect trastuzumab to gold nanoparticles, which will deliver gold nanoparticles specifically to BC cells. Once the nanoparticles are loaded in the tumor cells, focused X-rays will be delivered and the gold nanoparticles will produce a spray of electrons inside the tumors. Our laboratory has previously demonstrated that these electrons, called Auger electrons, are highly damaging to the DNA of the BC cells thereby killing them, and two of our products based on this principle are currently in Phase I/II clinical trials. Initial calculations suggest that this novel approach using gold nanoparticles could enhance the cell killing effects by as much as 250 times compared to X-rays alone.
Competitiondate
200811
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Chattopadhyay, Niladri
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $150,000~ $0~